Advertisement

Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review

      Abstract

      Introduction

      While surgery is the preferred option for isolated, operable liver metastases from colorectal cancer (CRC), ablative techniques are endorsed for medically or technically inoperable lesions. Stereotactic body radiotherapy (SBRT) is an alternative ablative local therapy that delivers high RT doses in a few fractions to the cancer, sparing surrounding critical tissue. We have performed a systematic review of published trials to evaluate the efficacy of SBRT as a primary modality therapy for CRC liver oligometastases.

      Materials and methods

      We searched the Cochrane Central Register of Controlled Trials, Pubmed, and EMBASE for publications regarding SBRT for CRC liver metastases. Overall survival (OS: median, 1- and 2-year OS %) was the primary endpoint, and median PFS and one- and two-year local control (LC) were the secondary endpoints. A random-effect model pooled-analysis was performed to calculate the aggregated OS rates at 1 and 2 years as well as the one- and two-year LC.

      Results

      A total of 18 studies, encompassing 656 patients, were included in the analysis. The pooled one- and two-year OS were 67.18% (95% CI, 42.1–92.2) and 56.5% (95% CI, 36.7–76.2), respectively. Median PFS and OS were 11.5 and 31.5 months. The pooled one-year LC was 67% (95% CI, 43.8–90.2), while the pooled two-year LC was 59.3% (95% CI, 37.2–81.5). Correlation analysis revealed a moderate/poor linear relationship between the SBRT (BED10) dose and LC (p = 0.001, R = 0.47)/OS (p = 0.001, R = 0.29) at 2 years. Mild-moderate and severe liver toxicity were 30.7% and 8.7%.

      Conclusion

      SBRT for liver oligometastases is an effective option for patients with advanced CRC, with encouraging local control and survival. However, a definitive validation in large randomised studies is required, due to the retrospective or non-randomised nature of the included studies and the limitations of series with different doses/schedules of treatment.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ruers T.
        • Van Coevorden F.
        • Punt C.J.A.
        • et al.
        Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial.
        J Natl Cancer Inst. 2017; 109: djx015https://doi.org/10.1093/jnci/djx015
        • Dawood O.
        • Mahadevan A.
        • Goodman K.A.
        Stereotactic body radiation therapy for liver metastases.
        Eur J Cancer. 2009; 45: 2947-2959https://doi.org/10.1016/j.ejca.2009.08.011
        • Fode M.M.
        • Høyer M.
        Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases.
        Radiother Oncol. 2015; 114: 155-160https://doi.org/10.1016/j.radonc.2014.12.003
        • Habermehl D.
        • Herfarth K.K.
        • Bermejo J.L.
        • et al.
        Single-dose radiosurgical treatment for hepatic metastases – therapeutic outcome of 138 treated lesions from a single institution.
        Radiat Oncol. 2013; 8https://doi.org/10.1186/1748-717X-8-175
        • Rusthoven K.E.
        • Kavanagh B.D.
        • Cardenes H.
        • et al.
        Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases.
        J Clin Oncol. 2009; 27: 1572-1578https://doi.org/10.1200/JCO.2008.19.6329
        • Klement R.J.
        Radiobiological parameters of liver and lung metastases derived from tumor control data of 3719 metastases.
        Radiother Oncol. 2017; 123: 218-226https://doi.org/10.1016/j.radonc.2017.03.014
        • Klement R.J.
        • Guckenberger M.
        • Alheid H.
        • et al.
        Stereotactic body radiotherapy for oligo-metastatic liver disease – Influence of pre-treatment chemotherapy and histology on local tumor control.
        Radiother Oncol. 2017; 123: 227-233https://doi.org/10.1016/j.radonc.2017.01.013
        • Kim H.
        • Gill B.
        • Beriwal S.
        • Huq M.S.
        • Roberts M.S.
        • Smith K.J.
        Cost-effectiveness analysis of stereotactic body radiation therapy compared with radiofrequency ablation for inoperable colorectal liver metastases.
        Int J Radiat Oncol Biol Phys. 2016; 95: 1175-1183https://doi.org/10.1016/j.ijrobp.2016.02.045
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        BMJ. 2009; 339https://doi.org/10.1136/bmj.b2535
        • Stang A.
        Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.
        Eur J Epidemiol. 2010; 25: 603-605https://doi.org/10.1007/s10654-010-9491-z
      1. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. In: The cochrane collaboration; 2011:Table 7.7.a: Formulae for combining groups.

        • Higgins J.P.T.
        • Thompson S.G.
        • Deeks J.J.
        • Altman D.G.
        Measuring inconsistency in meta-analyses.
        BMJ Br Med J. 2003; 327: 557-560https://doi.org/10.1136/bmj.327.7414.557
        • Ahmed K.A.
        • Caudell J.J.
        • El-Haddad G.
        • et al.
        Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy.
        Int J Radiat Oncol Biol Phys. 2016; 95: 1399-1404https://doi.org/10.1016/j.ijrobp.2016.03.050
        • Ambrosino G.
        • Polistina F.
        • Costantin G.
        • et al.
        Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results.
        Anticancer Res. 2009; 29: 3381-3384
        • Berber B.
        • Ibarra R.
        • Snyder L.
        • et al.
        Multicentre results of stereotactic body radiotherapy for secondary liver tumours.
        HPB. 2013; 15: 851-857https://doi.org/10.1111/hpb.12044
        • Chang D.T.
        • Swaminath A.
        • Kozak M.
        • et al.
        Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis.
        Cancer. 2011; 117: 4060-4069https://doi.org/10.1002/cncr.25997
        • Doi H.
        • Uemoto K.
        • Suzuki O.
        • et al.
        Effect of primary tumor location and tumor size on the response to radiotherapy for liver metastases from colorectal cancer.
        Oncol Lett. 2017; 14: 453-460https://doi.org/10.3892/ol.2017.6167
        • Goodman B.D.
        • Mannina E.M.
        • Althouse S.K.
        • Maluccio M.A.
        • Cárdenes H.R.
        Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases.
        Pract Radiat Oncol. 2016; 6: 86-95https://doi.org/10.1016/j.prro.2015.10.011
        • Hoyer M.
        • Roed H.
        • Hansen A.T.
        • et al.
        Phase II study on stereotactic body radiotherapy of colorectal metastases.
        Acta Oncol (Madr). 2006; 45: 823-830https://doi.org/10.1080/02841860600904854
        • Joo J.H.
        • Park J.
        • Kim J.C.
        • et al.
        Title: Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer.
        Int J Radiat Oncol. 2017; 99: 876-883https://doi.org/10.1016/j.ijrobp.2017.07.030
        • Kim M.-S.
        • Kang J.-K.
        • Cho C.K.
        • et al.
        Three-fraction stereotactic body radiation therapy for isolated liver recurrence from colorectal cancer.
        Tumori. 2009; 95: 449-454https://doi.org/10.1159/000201932
        • Lee M.T.
        • Kim J.J.
        • Dinniwell R.
        • et al.
        Phase I study of individualized stereotactic body radiotherapy of liver metastases.
        J Clin Oncol. 2009; 27: 1585-1591https://doi.org/10.1200/JCO.2008.20.0600
        • Liu E.
        • Stenmark M.H.
        • Schipper M.J.
        • et al.
        Stereotactic body radiation therapy for primary and metastatic liver tumors.
        Transl Oncol. 2013; 6: 442-446https://doi.org/10.1593/tlo.12448
        • McPartlin A.
        • Swaminath A.
        • Wang R.
        • et al.
        Long term outcomes of phase I and II studies of SBRT for hepatic colorectal metastases.
        Int J Radiat Oncol. 2017; 99: 388-395https://doi.org/10.1016/j.ijrobp.2017.04.010
        • Méndez Romero A.
        • Keskin-Cambay F.
        • van Os R.M.
        • et al.
        Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy.
        Rep Pract Oncol Radiother. 2017; 22: 126-131https://doi.org/10.1016/j.rpor.2016.10.003
        • Scorsetti M.
        • Comito T.
        • Tozzi A.
        • et al.
        Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer.
        J Cancer Res Clin Oncol. 2014; 141: 543-553https://doi.org/10.1007/s00432-014-1833-x
        • Stintzing S.
        • Grothe A.
        • Hendrich S.
        • et al.
        Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases.
        Acta Oncol (Madr). 2013; 52: 971-977https://doi.org/10.3109/0284186X.2013.766362
        • Van De Voorde L.
        • Vanneste B.
        • Houben R.
        • et al.
        Image-guided stereotactic ablative radiotherapy for the liver: a safe and effective treatment.
        Eur J Surg Oncol. 2015; 41: 249-256https://doi.org/10.1016/j.ejso.2014.10.053
        • van der Pool A.E.M.
        • Méndez Romero A.
        • Wunderink W.
        • et al.
        Stereotactic body radiation therapy for colorectal liver metastases.
        Br J Surg. 2010; 97: 377-382https://doi.org/10.1002/bjs.6895
        • Vautravers-Dewas C.
        • Dewas S.
        • Bonodeau F.
        • et al.
        Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship?.
        Int J Radiat Oncol Biol Phys. 2011; 81: 39-47https://doi.org/10.1016/j.ijrobp.2010.12.047
        • Tree A.C.
        • Khoo V.S.
        • Eeles R.A.
        • et al.
        Stereotactic body radiotherapy for oligometastases.
        Lancet Oncol. 2013; 14https://doi.org/10.1016/S1470-2045(12)70510-7
        • Takeda A.
        • Sanuki N.
        • Tsurugai Y.
        • Oku Y.
        • Aoki Y.
        Stereotactic body radiotherapy for patients with oligometastases from colorectal cancer: risk-adapted dose prescription with a maximum dose of 83–100 Gy in five fractions.
        J Radiat Res. 2016; 57: 400-405https://doi.org/10.1093/jrr/rrw029
        • Kang J.K.
        • Kim M.S.
        • Kim J.H.
        • et al.
        Oligometastases confined one organ from colorectal cancer treated by SBRT.
        Clin Exp Metastasis. 2010; 27: 273-278https://doi.org/10.1007/s10585-010-9325-0
        • Adam R.
        • Yi B.
        • Innominato P.F.
        • et al.
        Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients.
        Eur J Cancer. 2017; 78: 7-15https://doi.org/10.1016/j.ejca.2017.03.009
        • Fiorentini G.
        • Aliberti C.
        • Tilli M.
        • et al.
        Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: Final results of a phase III study.
        Anticancer Res. 2012; 32 (32/4/1387 [pii]): 1387-1395
        • Wong S.L.
        • Mangu P.B.
        • Choti M.A.
        • et al.
        American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer.
        J Clin Oncol. 2010; 28: 493-508https://doi.org/10.1200/JCO.2009.23.4450
        • van Amerongen M.J.
        • Jenniskens S.F.M.
        • van den Boezem P.B.
        • Fütterer J.J.
        • de Wilt J.H.W.
        Radiofrequency ablation compared to surgical resection for curative treatment of patients with colorectal liver metastases – a meta-analysis.
        HPB. 2017; 19: 749-756https://doi.org/10.1016/j.hpb.2017.05.011
        • Vogl T.J.
        • Farshid P.
        • Naguib N.N.N.
        • et al.
        Thermal ablation of liver metastases from colorectal cancer: radiofrequency, microwave and laser ablation therapies.
        Radiol Med. 2014; 119: 451-461https://doi.org/10.1007/s11547-014-0415-y
        • Wasan H.S.
        • Gibbs P.
        • Sharma N.K.
        • et al.
        First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.
        Lancet Oncol. 2017; 18: 1159-1171https://doi.org/10.1016/S1470-2045(17)30457-6
        • Saxena A.
        • Bester L.
        • Shan L.
        • et al.
        A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases.
        J Cancer Res Clin Oncol. 2014; 140: 537-547https://doi.org/10.1007/s00432-013-1564-4
        • Chau I.
        • Joulain F.
        • Iqbal S.U.
        • Bridgewater J.
        A VELOUR post hoc subset analysis: Prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI.
        BMC Cancer. 2014; 14
        • Kress M.-A.S.
        • Collins B.T.
        • Collins S.P.
        • Dritschilo A.
        • Gagnon G.
        • Unger K.
        Scoring system predictive of survival for patients undergoing stereotactic body radiation therapy for liver tumors.
        Radiat Oncol. 2012; 7: 148https://doi.org/10.1186/1748-717X-7-148
        • Hong T.S.
        • Wo J.Y.
        • Borger D.R.
        • et al.
        Phase II study of proton-based stereotactic body radiation therapy for liver metastases: importance of tumor genotype.
        JNCI J Natl Cancer Inst. 2017; 109: 1-8https://doi.org/10.1093/jnci/djx031